Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 12:13:999404.
doi: 10.3389/fphar.2022.999404. eCollection 2022.

Nanoparticle-based drug delivery systems for the treatment of cardiovascular diseases

Fangyu Yang  1 , Jianjiang Xue  1 , Guixue Wang  2 , Qizhi Diao  3
Affiliations
Review

Nanoparticle-based drug delivery systems for the treatment of cardiovascular diseases

Fangyu Yang et al. Front Pharmacol. .

Abstract

Cardiovascular disease is the most common health problem worldwide and remains the leading cause of morbidity and mortality. Despite recent advances in the management of cardiovascular diseases, pharmaceutical treatment remains suboptimal because of poor pharmacokinetics and high toxicity. However, since being harnessed in the cancer field for the delivery of safer and more effective chemotherapeutics, nanoparticle-based drug delivery systems have offered multiple significant therapeutic effects in treating cardiovascular diseases. Nanoparticle-based drug delivery systems alter the biodistribution of therapeutic agents through site-specific, target-oriented delivery and controlled drug release of precise medicines. Metal-, lipid-, and polymer-based nanoparticles represent ideal materials for use in cardiovascular therapeutics. New developments in the therapeutic potential of drug delivery using nanoparticles and the application of nanomedicine to cardiovascular diseases are described in this review. Furthermore, this review discusses our current understanding of the potential role of nanoparticles in metabolism and toxicity after therapeutic action, with a view to providing a safer and more effective strategy for the treatment of cardiovascular disease.

Keywords: cardiovascular diseases; drug delivery; nanomedicine; nanoparticles; nanotoxicity.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Nanoparticle-based drug delivery systems for the treatment of cardiovascular diseases.
FIGURE 2
FIGURE 2
Types of nanoparticles.
FIGURE 3
FIGURE 3
Nanomedicine-based strategies for targeting atherosclerotic plaques.
FIGURE 4
FIGURE 4
Nanotechnology applications in the advantages of reducing cardiotoxicity. Image adapted from Su et al. (2021).
FIGURE 5
FIGURE 5
Properties required for ideal nanoparticle.
See this image and copyright information in PMC

References

    1. Akagi S., Nakamura K., Matsubara H., Kondo M., Miura D., Matoba T., et al. (2016). Intratracheal administration of prostacyclin analogue-incorporated nanoparticles ameliorates the development of monocrotaline and sugen-hypoxia-induced pulmonary arterial hypertension. J. Cardiovasc. Pharmacol. 67 (4), 290–298. 10.1097/FJC.0000000000000352 - DOI - PMC - PubMed
    1. Akagi S., Nakamura K., Miura D., Saito Y., Matsubara H., Ogawa A., et al. (2015). Delivery of imatinib-incorporated nanoparticles into lungs suppresses the development of monocrotaline-induced pulmonary arterial hypertension. Int. Heart. J. 56, 354–359. 10.1536/ihj.14-338 - DOI - PubMed
    1. Alam T., Khan S., Gaba B., Haider M. F., Baboota S., Ali J. (2017). Nanocarriers as treatment modalities for hypertension. Drug. Deliv. 24 (1), 358–369. 10.1080/10717544.2016.1255999 - DOI - PMC - PubMed
    1. Baigent C., Baigent L., Blackwell R., Collins J., Emberson J., Godwin R., et al. (2009). Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet 373 (9678), 1849–1860. 10.1016/S0140-6736(09)60503-1 - DOI - PMC - PubMed
    1. Ballinger S. W., Patterson C., Knight-Lozano C. A., Burow D. L., Conklin C. A., Hu Z., et al. (2002). Mitochondrial integrity and function in atherogenesis. Circulation 106 (5), 544–549. 10.1161/01.cir.0000023921.93743.89 - DOI - PubMed

LinkOut - more resources